Sildenafil citrateProduct ingredient for Sildenafil

Keywords: Sildenafil citrate, Sildenafil citrate supplier, phosphodiesterases, 5, PDE5, inhibitors, inhibits, orally, active, potent, HSC, hematopoietic, haematopoietic, stem, cells, mobilization, COVID-19, pulmonary, edema, Phosphodiesterases, Stem, Cell, Proliferation, Hematopoietic, Cells, 3784, Tocris Bioscience Citations are publications that use Tocris products. Vandendriessche et al (2013) The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems.

Parameter	Frequency	Purpose	Notes
Blood Pressure	Before and after dosage	Check for hypotension	Especially in high-risk groups
Visual Function	Periodic	Monitor for retinal issues	Baseline and follow-up
Liver Function Tests	As needed	Detect hepatotoxicity	For long-term users

Xiaofeng et al (2021) Intracellular H2S production is an autophagy-dependent adaptive response to DNA damage.

Parameter	Value	Description	Notes
Absorption	Rapid	Peak plasma levels in 30-120 mins	After oral administration
Bioavailability	40%	Percentage of dose reaching systemic circulation	Subject to food effects
Half-life	4 hours	Time for plasma concentration to reduce by half	---
Metabolism	Liver (CYP3A4 enzymes)	Mainly via CYP3A4 and CYP2C9
Excretion	Feces and urine	80% via feces, 13% via urine

Cell Chem Biol 28 1669-1678.e5 PMID: 34166610 Do you know of a great paper that uses Sildenafil citrate from Tocris?

Pregnancy & Lactation

Data show no significant differences between baseline and post–placebo treatment scores, except for question 13 (relationship satisfaction), which was significantly better after placebo treatment. The 5 IIEF domains are listed in Table 2. No significant differences between placebo and baseline scores were detected in any domain. There are currently no reviews for this product. Be the first to review Sildenafil citrate and earn rewards! $25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image Departments of Nephrology and Urology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India Received December 27, 2005; Accepted April 10, 2006; Published online May 24, 2006 Originally published online as doi:10.1053/j.ajkd.2006.04.061 on May 24, 2006.

Product	Dosage	Quantity + Bonus	Price
Kamagra Soft Tabs	100mg	120 + 6 Pills	311.78€ 296.93€	Buy
Viagra Generic	100mg	180 + 8 Pills	199.37€ 189.88€	Buy
Viagra Generic	150mg	10 Pills	36.73€ 34.98€	Buy
Viagra Generic	100mg	270 + 10 Pills	270.47€ 257.59€	Buy
Viagra Generic	100mg	360 + 10 Pills	330.21€ 314.49€	Buy
Kamagra Oral Jelly	100mg	30 + 5 Sachets	136.20€ 129.71€	Buy
Viagra Generic	25mg	30 + 4 Pills	47.97€ 45.69€	Buy
Viagra Generic	200mg	20 Pills	61.69€ 58.75€	Buy
Viagra Generic	25mg	180 + 6 Pills	154.93€ 147.55€	Buy
Viagra Generic	25mg	90 + 6 Pills	105.03€ 100.03€	Buy
Viagra Generic	200mg	120 + 8 Pills	204.80€ 195.05€	Buy
Viagra Generic	150mg	360 + 10 Pills	423.48€ 403.31€	Buy
Kamagra	100mg	84 + 6 Pills	264.44€ 251.85€	Buy

Support: Zydus Cadila provided placebo and sildenafil tablets. DOI: 10.1053/j.ajkd.2006.04.061 External LinkAlso available on ScienceDirect External Link ERECTILE DYSFUNCTION (ED) is the persistent inability to achieve a sustained erection sufficient for satisfactory sexual performance. The mental stress resulting from ED affects patients’ interactions with family and others.1 ED is observed frequently in patients with end-stage renal disease and patients on hemodialysis therapy, and the estimated prevalence is between 71% and 82% in these patients.2,3 Only up to 75% of these patients recover from ED after renal transplantation.4 ED also may occur in up to a third of patients receiving a double transplant with vascular anastomosis to the hypogastric artery because of reduced arterial flow to the penis.5 Treatment options for men with ED include psychosexual therapy, drug therapy, transurethral or intracavernosal therapy, treatment with vacuum constriction devices, and surgical treatment.6 Sildenafil citrate is a selective inhibitor of phosphodiesterase type 5, which is the predominant isozyme interacting with cyclic guanosine monophosphate in corpus cavernosum and results in increased smooth muscle relaxation and improved erection. Recently, sildenafil was shown to be an effective, safe, and well-tolerated drug for men with ED7 and end-stage renal disease and maintenance hemodialysis patients with ED.8-11 There are few either nonrandomized or uncontrolled studies on the use of sildenafil in renal allograft recipients.12-16 There have been no double-blind placebo-controlled studies with sildenafil in renal allograft recipients. The area under the curve (AUC) of cyclosporine before and after sildenafil therapy was not compared in any of these studies.12-16 Therefore, we conducted a randomized, double-blind, placebo-controlled, crossover study to establish the safety and efficacy of sildenafil in renal transplant recipients with ED.

Related/similar drugs

Patients were instructed to take a single dose of study medication in a day, not more than once daily. The initial dose was 50 mg of sildenafil citrate or placebo of identical appearance. Based on the investigator’s judgment of efficacy and tolerability, the dose could be increased to 100 mg or decreased to 25 mg of sildenafil or placebo. The initial dose of the drug was taken 1 hour before sexual intercourse, avoiding heavy meals or excessive alcohol intake. All patients completed the International Index of Erectile Function (IIEF) and a diary card to record response to the drug and the occurrence of side effects.

Postmarketing Reports

Efficacy was assessed by using the self-administered IIEF, a 15-question validated measure of ED,17,18 and a global efficacy question (Did the treatment improve your erection? The IIEF system is used for clinical assessment of ED and treatment outcome in clinical studies. It evaluates several aspects of sexual performance, rating each answer from 0 to 5, with 0 meaning no sexual activity/no attempt at sexual intercourse, 1 meaning the worst response (almost never/never), and 5 meaning the best response (almost always/always). Total score ranges from 5 to 75. Treatment efficacy was assessed through the answer to questions 3 (penetration ability) and 4 (maintenance frequency). The study is designed as a randomized, double-blind, placebo-controlled, crossover trial. Inclusion criteria for patients were renal transplant recipients who: (1) had stable graft function in the last 6 months, (2) were 18 years and older, (3) had medically documented ED as defined by the National Institute of Health Consensus Panel,1 and (4) were in a stable relationship with a female partner in the last 6 months.

• Sildenafil can cause sudden vision loss (rare side effect).
• Men with a history of retina problems should use caution.
• It may cause a drop in blood pressure, leading to dizziness.
• Patients should report any persistent erection lasting over 4 hours.
• It is crucial to have proper medical evaluation before use.
• Not suitable for individuals with severe liver or kidney conditions.
• The medication is also investigated for breast cancer treatment.
• Proper hydration can help minimize some side effects.

All patients were subjected to a detailed medical history and physical examination that included blood liquid sildenafil citrate pressure, pulse rate, 12-lead electrocardiogram, cyclosporine A level by means of enzyme multiplied immunoassay method, and standard biochemistry (blood urea nitrogen, serum creatinine) and hematologic tests (hemoglobin, total and differential leukocyte count, and platelet count) at baseline and after each crossover. Exclusion criteria included the following: (1) penile anatomic deformities, (2) history of recent stroke, (3) myocardial infarction in the previous 6 months, (4) proliferative diabetic retinopathy, (5) severe autonomic neuropathy, (6) regular treatment with nitrates and androgens, and (7) spinal cord injury. At week 0, each eligible patient was given a randomization number that followed a randomization table generated by the method of random permuted blocks. The system generating the randomization assignment was operationally independent from study investigators who executed the randomization assignment and conducted the study. Renal allograft recipients with ED were divided into 2 groups, the placebo group and sildenafil group, by randomization and then crossed over to another group after 8 weeks in a double-blind manner. The washout period of 2 weeks was ensured in each patient during crossover from 1 group to the other by the investigator.

• Sildenafil citrate is also used in veterinary medicine.
• It helps treat pulmonary hypertension in animals.
• Studies explore its effects on canine health.
• Animal dosage differs from human recommendations.
• Veterinary formulations are specially designed.
• Usage should always be under professional supervision.
• Research continues into broader applications in animals.
• Ethical guidelines govern its veterinary use.

Patients were instructed to take a single dose of study medication in a day, not more than once daily.

Notes et références

Keywords: Sildenafil citrate, Sildenafil citrate supplier, phosphodiesterases, 5, PDE5, inhibitors, inhibits, orally, active, potent, HSC, hematopoietic, haematopoietic, stem, cells, mobilization, COVID-19, pulmonary, edema, Phosphodiesterases, Stem, Cell, Proliferation, Hematopoietic, Cells, 3784, Tocris Bioscience Citations are publications that use Tocris products. Vandendriessche et al (2013) The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems. Xiaofeng et al (2021) Intracellular H2S production is an autophagy-dependent adaptive response to DNA damage. Cell Chem Biol 28 1669-1678.e5 PMID: 34166610 Do you know of a great paper that uses Sildenafil citrate from Tocris? There are currently no reviews for this product.

Recreational use

Be the first to review Sildenafil citrate and earn rewards! $25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image Departments of Nephrology and Urology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India Received December 27, 2005; Accepted April 10, 2006; Published online May 24, 2006 Originally published online as doi:10.1053/j.ajkd.2006.04.061 on May 24, 2006. Support: Zydus Cadila provided placebo and sildenafil tablets. DOI: 10.1053/j.ajkd.2006.04.061 External LinkAlso available on ScienceDirect External Link ERECTILE DYSFUNCTION (ED) is the persistent inability to achieve a sustained erection sufficient for satisfactory sexual performance. The mental stress resulting from ED affects patients’ interactions with family and others.1 ED is observed frequently in patients with end-stage renal disease and patients on hemodialysis therapy, and the estimated prevalence is between 71% and 82% in these patients.2,3 Only up to 75% of these patients recover from ED after renal transplantation.4 ED also may occur in up to a third of patients receiving a double transplant with vascular anastomosis to the hypogastric artery because of reduced arterial flow to the penis.5 Treatment options for men with ED include psychosexual therapy, drug therapy, transurethral or intracavernosal therapy, treatment with vacuum constriction devices, and surgical treatment.6 Sildenafil citrate is a selective inhibitor of phosphodiesterase type 5, which is the predominant isozyme interacting with cyclic guanosine monophosphate in corpus cavernosum and results in increased smooth muscle relaxation and improved erection. The initial dose was 50 mg of sildenafil citrate or placebo of identical appearance. Based on the investigator’s judgment of efficacy and tolerability, the dose could be increased to 100 mg or decreased to 25 mg of sildenafil or placebo. The initial dose of the drug was taken 1 hour before sexual intercourse, avoiding heavy meals or excessive alcohol intake. All patients completed the International Index of Erectile Function (IIEF) and a diary card to record response to the drug and the occurrence of side effects. Efficacy was assessed by using the self-administered IIEF, a 15-question validated measure of ED,17,18 and a global efficacy question (Did the treatment improve your erection? The IIEF system is used for clinical assessment of ED and treatment outcome in clinical studies. It evaluates several aspects of sexual performance, rating each answer from 0 to 5, with 0 meaning no sexual activity/no attempt at sexual intercourse, 1 meaning the worst response (almost never/never), and 5 meaning the best response (almost always/always). Total score ranges from 5 to 75. Treatment efficacy was assessed through the answer to questions 3 (penetration ability) and 4 (maintenance frequency). Efficacy also was evaluated through the score for the 5 separate response domains of male sexual function of the IIEF: erectile function (questions 1 to 5 and 15; total score, 1 to 30), intercourse satisfaction (questions 6 to 8; total score, 0 to 15), orgasmic function (questions 9 and 10; total score, 0 to 10), sexual desire (questions 11 and 12; total score, 2 to 10), and overall satisfaction (questions 13 and 14; total score, 2 to 10). The final score of each domain is the sum of scores for individual questions in that domain.

What other information should I know?

Efficacy also was evaluated through the score for the 5 separate response domains of male sexual function of the IIEF: erectile function (questions 1 to 5 and 15; total score, 1 to 30), intercourse satisfaction (questions 6 to 8; total score, 0 to 15), orgasmic function (questions 9 and 10; total score, 0 to 10), sexual desire (questions 11 and 12; total score, 2 to 10), and overall satisfaction (questions 13 and 14; total score, 2 to 10). The final score of each domain is the sum of scores for individual questions in that domain. Patients with a score of 26 or higher on the erectile function domain were considered to have no ED and were excluded from analysis. In a selected group of 5 patients with normal graft function, cyclosporine level was estimated at 0-, 0.5-, 1-, 2-, 3-, 4-, and 6-hour intervals with and without sildenafil, and the AUC of cyclosporine level was estimated to see the effect of sildenafil on cyclosporine level. AUC was estimated by using a linear trapezoid rule.

How is sildenafil supplied (dosage forms)?

The study was conducted at Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, a tertiary-care academic institute. Informed consent was obtained from all patients included in the study. Both sildenafil and placebo of identical aspect were provided by Zydus Cadila (Ahmedabad, India) free of charge. The authors received no other support from the drug and placebo provider to avoid any conflict of interest. Mean ± SD was calculated for each IIEF question or domain. Patients with a score of 26 or higher on the erectile function domain were considered to have no ED and were excluded from analysis. In a selected group of 5 patients with normal graft function, cyclosporine level was estimated at 0-, 0.5-, 1-, 2-, 3-, 4-, and 6-hour intervals with and without sildenafil, and the AUC of cyclosporine level was estimated to see the effect of sildenafil on cyclosporine level. AUC was estimated by using a linear trapezoid rule. The study was conducted at Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, a tertiary-care academic institute. Informed consent was obtained from all patients included in the study. Both sildenafil and placebo of identical aspect were provided by Zydus Cadila (Ahmedabad, India) free of charge. The authors received no other support from the drug and placebo provider to avoid any conflict of interest.

Chemical synthesis

At end of the study, mean numbers of tablets of sildenafil and placebo taken by patients were 24.3 ± 3.3 and 23.8 ± 2.6, respectively (P = 0.49). Table 1 lists scores for each of the 15 IIEF questions. After treatment with sildenafil, patients administered sildenafil had highly significantly better scores in 13 of 15 questions. The only questions for which differences were not significant were questions 11 (desire frequency; P = 0.39) and 12 (desire level; P = 0.61). Treatment efficacy assessed through questions 3 (penetration ability; P < 0.001) and 4 (maintenance frequency; P < 0.001) was significantly better after sildenafil therapy. Mean ± SD was calculated for each IIEF question or domain. Results of the placebo and sildenafil groups were compared by using t-test and Mann-Whitney U test for parametric and nonparametric sildenafil tablet manforce 50 mg data, respectively. Comparison of basal and final results in each group was performed by using paired t-test and Wilcoxon test for parametric and nonparametric data, respectively. Thirty-two eligible renal transplant recipients were included in this study. Mean duration of the transplant was 4.7 ± 3 years, duration of ED was 17 ± 22 months, and duration of dialysis therapy was 3.5 ± 2 months.

• Sildenafil citrate is a medication used primarily to treat erectile dysfunction.
• It belongs to the class of drugs called phosphodiesterase type 5 inhibitors.
• Sildenafil was originally developed to treat angina and hypertension.
• The drug works by increasing blood flow to the penis during stimulation.
• It is commonly sold under the brand name Viagra.
• Sildenafil is available by prescription and as generics.
• The typical dose is 50 mg taken about an hour before activity.
• Common side effects include headaches, flushing, and nasal congestion.

All patients had undergone living-related transplantations. No patient in our study had a vascular anastomosis to both the internal iliac artery and hypogastric artery. Of these patients, 14 patients had chronic glomerulonephritis, 8 patients had chronic interstitial nephritis, 7 patients had diabetic nephropathy, and 3 patients had other basic diseases. No patient had autonomic neuropathy at time of enrollment into this study. At baseline, mean hemoglobin level was 12.3 ± 1.5 g/dL (123 ± 15 g/L), mean blood urea nitrogen level was 18.3 ± 7.6 mg/dL (6.53 ± 2.71 mmol/L), and creatinine level was 1.48 ± 0.3 mg/dL (131 ± 27 μmol/L). In total, 32 tablets of sildenafil or placebo were offered to patients during the study period.

Voir aussi

Results of the placebo and sildenafil groups were compared by using t-test and Mann-Whitney U test for parametric and nonparametric sildenafil tablet manforce 50 mg data, respectively. Comparison of basal and final results in each group was performed by using paired t-test and Wilcoxon test for parametric and nonparametric data, respectively. Thirty-two eligible renal transplant recipients were included in this study. Mean duration of the transplant was 4.7 ± 3 years, duration of ED was 17 ± 22 months, and duration of dialysis therapy was 3.5 ± 2 months. All patients had undergone living-related transplantations.

Revatio for Oral Suspension

No patient in our study had a vascular anastomosis to both the internal iliac artery and hypogastric artery. Of these patients, 14 patients had chronic glomerulonephritis, 8 patients had chronic interstitial nephritis, 7 patients had diabetic nephropathy, and 3 patients had other basic diseases. No patient had autonomic neuropathy at time of enrollment into this study. At baseline, mean hemoglobin level was 12.3 ± 1.5 g/dL (123 ± 15 g/L), mean blood urea nitrogen level was 18.3 ± 7.6 mg/dL (6.53 ± 2.71 mmol/L), and creatinine level was 1.48 ± 0.3 mg/dL (131 ± 27 μmol/L). In total, 32 tablets of sildenafil or placebo were offered to patients during the study period. At end of the study, mean numbers of tablets of sildenafil and placebo taken by patients were 24.3 ± 3.3 and 23.8 ± 2.6, respectively (P = 0.49). Table 1 lists scores for each of the 15 IIEF questions.

Other Uses for Sildenafil

Recently, sildenafil was shown to be an effective, safe, and well-tolerated drug for men with ED7 and end-stage renal disease and maintenance hemodialysis patients with ED.8-11 There are few either nonrandomized or uncontrolled studies on the use of sildenafil in renal allograft recipients.12-16 There have been no double-blind placebo-controlled studies with sildenafil in renal allograft recipients. The area under the curve (AUC) of cyclosporine before and after sildenafil therapy was not compared in any of these studies.12-16 Therefore, we conducted a randomized, double-blind, placebo-controlled, crossover study to establish the safety and efficacy of sildenafil in renal transplant recipients with ED. The study is designed as a randomized, double-blind, placebo-controlled, crossover trial. Inclusion criteria for patients were renal transplant recipients who: (1) had stable graft function in the last 6 months, (2) were 18 years and older, (3) had medically documented ED as defined by the National Institute of Health Consensus Panel,1 and (4) were in a stable relationship with a female partner in the last 6 months. All patients were subjected to a detailed medical history and physical examination that included blood liquid sildenafil citrate pressure, pulse rate, 12-lead electrocardiogram, cyclosporine A level by means of enzyme multiplied immunoassay method, and standard biochemistry (blood urea nitrogen, serum creatinine) and hematologic tests (hemoglobin, total and differential leukocyte count, and platelet count) at baseline and after each crossover.

Patient resources

Exclusion criteria included the following: (1) penile anatomic deformities, (2) history of recent stroke, (3) myocardial infarction in the previous 6 months, (4) proliferative diabetic retinopathy, (5) severe autonomic neuropathy, (6) regular treatment with nitrates and androgens, and (7) spinal cord injury. At week 0, each eligible patient was given a randomization number that followed a randomization table generated by the method of random permuted blocks. The system generating the randomization assignment was operationally independent from study investigators who executed the randomization assignment and conducted the study. Renal allograft recipients with ED were divided into 2 groups, the placebo group and sildenafil group, by randomization and then crossed over to another group after 8 weeks in a double-blind manner. The washout period of 2 weeks was ensured in each patient during crossover from 1 group to the other by the investigator. After treatment with sildenafil, patients administered sildenafil had highly significantly better scores in 13 of 15 questions. The only questions for which differences were not significant were questions 11 (desire frequency; P = 0.39) and 12 (desire level; P = 0.61). Treatment efficacy assessed through questions 3 (penetration ability; P < 0.001) and 4 (maintenance frequency; P < 0.001) was significantly better after sildenafil therapy. Data show no significant differences between baseline and post–placebo treatment scores, except for question 13 (relationship satisfaction), which was significantly better after placebo treatment. The 5 IIEF domains are listed in Table 2. No significant differences between placebo and baseline scores were detected in any domain.